Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Real World Outcomes Using Novel Agents for Acute Myeloid Leukaemia in the United Kingdom

ID
Name
305432
Description
This project will collect data on patients with acute myeloid leukemia in the United Kingdom who were treated with two new targeted therapies during the coronavirus pandemic
Trial arms
Trial start
2022-05-01
Estimated PCD
2023-10-01
Trial end
2023-10-01
Status
Recruiting
Treatment
Venetoclax
Observational study of venetoclax in AML
Arms:
Venetoclax
Other names:
Venclyxto
Gilteritinib
Observational study of gilteritinib in AML
Arms:
FLT3 inhibitors
Other names:
Xospata
Size
1000
Primary endpoint
Overall survival
1 year
Early death rate
Day 60 after starting treatment
Eligibility criteria
Venetoclax cohort Inclusion criteria 1. Newly diagnosed acute myeloid leukaemia 2. No prior therapies for AML, apart from hydroxyurea (or similar) for cytoreduction. Previous treatments for MDS or other conditions are allowed 3. Treated with venetoclax in combination with either azacitidine or LDAC No exclusion criteria Gilteritinib/FLT3 cohort Inclusion criteria 1. Relapsed acute myeloid leukaemia, including molecular relapse 2. Treated with FLT3 inhibitor No exclusion criteria
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 1000, 'type': 'ESTIMATED'}}
Updated at
2023-03-02

1 organization

2 products

1 indication

Organization
Guy's and St Thomas' NHS Foundation Trust
Product
Venetoclax
Indication
Acute Myeloid Leukemia
Product
Gilteritinib